Wragge & Co’s life sciences team has brokered a licensing agreement between AstraZeneca and a partnership of Belgian life sciences research institutes: the Biotechnology Institute VIB, CD3 and KU Leuven.
The deal will see AstraZeneca in-license certain novel molecules from VIB/CD3 and collaborate with academics to explore new insights into treatments for inflammatory and cancer diseases.
The agreement, negotiated and drafted by the Wragge & Co team in three weeks, secures long-term research funding to explore the potential of MALT1 — a naturally occurring protein — as a promising target for potential new treatments of auto-immune disorders and certain types of cancer.
Wragge & Co’s life sciences team worked across several jurisdictions including Sweden, Belgium and the US to secure the agreement and research will begin imminently. Partner Dr Luke Kempton led on the deal for the law firm.